trastuzumab deruxtecan + rilvegostomig + capecitabine

This is a **combination therapy** comprised of trastuzumab deruxtecan, rilvegostomig, and capecitabine under active clinical investigation, primarily for **HER2-positive and HER2-low gastric, gastroesophageal junction, and esophageal adenocarcinoma**. - **Trastuzumab deruxtecan** is an antibody-drug conjugate that binds HER2 and delivers a topoisomerase I inhibitor payload via a cleavable tetrapeptide linker, resulting in targeted cytotoxicity to HER2-expressing tumor cells. - **Rilvegostomig** is a bispecific monoclonal antibody targeting both PD-1 and TIGIT, designed to enhance antitumor immune activity by checkpoint inhibition. - **Capecitabine** is a fluoropyrimidine chemotherapy prodrug metabolized into 5-fluorouracil (5-FU), which disrupts DNA synthesis in proliferating cells. This regimen is currently in **Phase 2 and Phase 3 clinical trials** as neoadjuvant, adjuvant, and first-line treatment in HER2-positive and HER2-low populations, often as an alternative to combinations with pembrolizumab or other chemotherapy[1][2][3][4]. Developers and sponsors include AstraZeneca and Daiichi Sankyo.

Brand names

Enhertu

Other names

trastuzumab deruxtecan + rilvegostomig + capecitabine